📖

ABI3 Gene

active

wiki page Created: 2026-04-02T20:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-abi3

Related Entities

ABI3

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

📊 Evidence Profile

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

141

Outgoing

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Linked Artifacts (166)

mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides70%

mentions🧪APOE Isoform Conversion Therapy70%

mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy70%

see_also📖Amyloid Conformational Strains60%

see_also📖NBR1 Gene60%

see_also📖Complement Inhibitor Therapy in Neurodegeneration60%

see_also📖amyloid-beta-metalloproteinases60%

see_also📖Progranulin Protein60%

see_also📖SORL1 Gene60%

see_also📖EED60%

see_also📖Amyloid-beta Fibril Formation Pathway60%

see_also📖LILRB2 — Leukocyte Immunoglobulin-Like Receptor B260%

see_also📖CTSH Gene60%

see_also📖Tau vs TDP-43 Fate Switching in Frontotemporal Dementia60%

see_also📖APP Gene Dosage Reduction Therapy for Down Syndrome60%

see_also📖Complement Activation in Corticobasal Degeneration60%

see_also📖Complement Component 3 (C3)60%

see_also📖Tau Proteostasis and Clearance Across 4R-Tauopathies60%

see_also📖Complement System Therapeutics for Neurodegeneration60%

see_also📖PSEN1 Protein (Presenilin-1)60%

see_also📖Amyloid vs Tau-First Hypothesis60%

see_also📖Amyloid-Tau Synergistic Interaction Hypothesis in Alzheimer&60%

see_also📖Tau Pathology Severity Assessment Model — Braak Staging and 60%

see_also📖Hippocampal CA1 Pyramidal Neurons60%

see_also📖Complement System in Neurodegeneration60%

see_also📖amyloid-responsive-microglia60%

see_also📖Autophagy Enhancement Drug Screening for Neurodegeneration60%

see_also📖Granulovacuolar Bodies: Neuronal Defense Mechanism Against T60%

see_also📖Tau ASO Therapy60%

see_also📖Amyloid PET Imaging60%

see_also📖Total Tau (t-Tau) - Biomarker60%

see_also📖Complement System Pathway in Neurodegeneration60%

see_also📖entities-psen160%

see_also📖Amyloid PET Imaging - Diagnostic Biomarker60%

see_also📖TREM2 Protein (Triggering Receptor Expressed on Myeloid Cell60%

see_also📖ACE Gene60%

see_also📖Tau Oligomers60%

see_also📖SORL1 Protein60%

see_also📖Tau Protein60%

see_also📖Amyloid Beta 40 (Aβ40) - Biomarker60%

see_also📖CD33 (Siglec-3)60%

see_also📖Alzheimer Indonesia60%

see_also📖amyloid-cascade-hypothesis60%

see_also📖tau-pet-4r-tauopathies60%

see_also📖Amyloid-beta Oligomerization Pathway60%

see_also📖Complement Dysregulation in CBS and 4R Tauopathies60%

see_also📖Complement System Dysregulation in Neurodegeneration - Resea60%

see_also📖Amyloid-beta Cellular Uptake Pathway60%

see_also📖Tau-Seed Interception Using Conformational-Selective Extrace60%

see_also📖Tau-PROTAC Heterobifunctional Degrader for Tauopathy60%

see_also📖ABCA1 - ATP-Binding Cassette Transporter A160%

see_also📖complement-c1q-inhibitor-therapy60%

see_also📖LRP1-Enhanced Perivascular Drainage Therapy60%

see_also📖PLCG2 Gene60%

see_also📖SORL1 (Redirect)60%

see_also📖Amyloid-Tau Synergistic Interaction Hypothesis60%

see_also📖amyloid-beta-cellular-uptake60%

see_also📖Amyloid-Beta-Exposed Neurons60%

see_also📖Amyloid Therapeutics: Investment Landscape Analysis60%

see_also📖GRN — Progranulin60%

see_also📖Tau Pathology Astrocytes (TPA)60%

see_also📖Amyloid-beta Trans-synaptic Spread Pathway60%

see_also📖Tau Consortium60%

see_also📖Complement Pathway Inhibition Therapy for Neurodegeneration60%

see_also📖PSEN1 — Presenilin 160%

see_also📖Amyloid-beta Fibril Formation60%

see_also📖CD2AP Gene — CD2-Associated Protein60%

see_also📖clu60%

see_also📖Amyloid-Beta Clearance Therapeutic Pathways60%

see_also📖Complement and Coagulation Systems in 4R-Tauopathies60%

see_also📖TMEM106B60%

see_also📖TREM2 — Triggering Receptor Expressed on Myeloid Cells 260%

see_also📖Amyloid-Related Imaging Abnormalities (ARIA)60%

see_also📖entities-grn60%

see_also📖Complement-Mediated Synapse Loss60%

see_also📖Amyloid-Beta Metabolism in Cortical Neurons60%

see_also📖PICALM — Phosphatidylinositol Binding Clathrin Assembly Prot60%

see_also📖Actin Cytoskeleton Dynamics in Neurodegeneration60%

see_also📖TMEM106B Lysosomal Restoration Therapy for Neurodegeneration60%

see_also📖hypotheses-apoe-contributes-alzheimers-disease-regulat60%

see_also📖Amyloid vs Tau-First Hypothesis in Alzheimer's Disease60%

see_also📖amyloid-hypothesis60%

see_also📖Complement System Activation in Neurodegeneration60%

see_also📖INPP5D — Inositol Polyphosphate-5-Phosphatase D (SHIP1)60%

see_also📖TMEM106B Protein (Transmembrane Protein 106B)60%

see_also📖oga-inhibition-tau60%

see_also📖trem2-alpha-synuclein-clearance-parkinsons60%

see_also📖cd3360%

see_also📖Amyloid Immunotherapy Vaccines for Alzheimer's Disease60%

see_also📖LRP1 Gene60%

see_also📖Amyloid-beta Degradation Pathways60%

see_also📖CTSB Gene60%

see_also📖Tau PET Imaging in Neurodegenerative Disease60%

see_also📖TREM2 Protein60%

see_also📖CD33 Modulation Therapy for Neurodegeneration60%

see_also📖Complement System in Neurodegeneration60%

see_also📖SORL1 Protein60%

see_also📖TREM2 Mechanism Hub60%

see_also📖Amyloid plaque and neurofibrillary tangle deposition is an e60%

see_also📖LRP1-Targeted ApoE-Mimetic Peptide Delivery60%

see_also📖SPI1 Gene - PU.160%

see_also📖Amyloid Precursor Protein (APP)60%

see_also📖adam1760%

see_also📖Amyloid Oligomers in Neurodegeneration60%

see_also📖TMEM106B — Transmembrane Protein 106B60%

see_also📖Amyloid Cascade Pathway60%

see_also📖Amyloid-Beta Accumulating Neurons60%

see_also📖ptk2b60%

see_also📖Advanced Immunotherapy Platforms for Tau60%

see_also📖Epidemic Spreading Model of Tau Pathology60%

see_also📖Amyloid-Beta Aggregation and Plaque Formation60%

see_also📖LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1)60%

see_also📖CR1 Gene — Complement Component 1q Receptor60%

see_also📖bin160%

see_also📖p-tau60%

see_also📖amyloid-cascade-pathway60%

see_also📖Phage Display and Directed Evolution for Tau Therapeutics60%

see_also📖GRN Carrier Resilience: Why Some Mutation Carriers Remain As60%

see_also📖Amyloid-Beta-Exposed Neurons60%

see_also📖Tau Co-Pathology in DLB Clinical Heterogeneity60%

mentions🧪Competitive APOE4 Domain Stabilization Peptides50%

mentions🧪TREM2-mediated microglial tau clearance enhancement50%

mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia50%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%

mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination50%

mentions🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th50%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%

mentions🧪CYP46A1 Overexpression Gene Therapy50%

mentions🧪APOE Isoform Expression Across Glial Subtypes50%

see_also📖nct0550878945%

see_also📖LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy for 45%

see_also📖remternetug-anti-amyloid-alzheimers45%

see_also📖LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE45%

see_also📖BEACoN Study - Biomarker Exploration in Aging, Cognition and45%

see_also📖UPenn Observational Research Repository (NCT04715399)45%

mentions🔬Analyze circuit-level changes in neurodegeneration using All40%

related🧪APOE Isoform Conversion Therapy40%

ABI3 Gene

💬 Discussion